Ropes & Gray represented Prevail Therapeutics in a $75 million Series A financing announced on March 8.
Investors in the round included OrbiMed, Pontifax, RA Capital, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital LLC, Adage Capital Management L.P., and Alexandria Venture Investments. OrbiMed and the Silverstein Foundation for Parkinson’s with GBA incubated and provided seed funding to Prevail.
Prevail is a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. The proceeds of the Series A financing will be used to advance Prevail’s pipeline of adeno-associated virus therapeutics targeting lysosomal dysfunction to treat patients with genetically-defined neurodegenerative diseases.
The Ropes & Gray team was led by life sciences partner Marc Rubenstein and included life sciences associate Brad Flint (both of Boston).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.